Companies › Minovia Therapeutics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology, Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MNV-201 Autologous CD34+ cells enriched with allogeneic placenta-derived mitochondria | – | Phase 2 | Mitochondrial Diseases; Myelodysplastic Syndromes | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06465160 | MNV-201 | Phase 1 | Myelodysplastic Syndromes | Hematology | Dec 2026 |
| NCT06017869 | MNV-201 | Phase 2 | Mitochondrial Diseases | Neurology | Dec 2027 |
No annotated target.
–
Nippon Shinyaku MED Institute NeuroPace Shanghai Xinzhi BioMed Sarepta Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.